Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis
about
Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitisSteroidogenesis in the skin: implications for local immune functionsLocal blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing.Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores.Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroidsPPARgamma activators stimulate aquaporin 3 expression in keratinocytes/epidermis.Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis.Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin.Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?11β-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair.Nuclear receptor function in skin health and disease: therapeutic opportunities in the orphan and adopted receptor classes.AP1-dependent repression of TGFα-mediated MMP9 upregulation by PPARδ agonists in keratinocytes.Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment.11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Attenuates the Adverse Effects of Glucocorticoids on Dermal Papilla Cells.The effect of a corticosteroid cream and a barrier-strengthening moisturizer in hand eczema. A double-blind, randomized, prospective, parallel group clinical trial.Topical application of a linoleic acid-ceramide containing moisturizer exhibit therapeutic and preventive benefits for psoriasis vulgaris: a randomized controlled trial.
P2860
Q26827984-AC47496F-EF54-43EA-A600-FC2BEBD8ADAEQ26830355-48DCA801-2373-4FCB-8EB7-EB3AE4EFDA8FQ30658259-4FBFC46A-D363-4245-A73A-6B625F658CBEQ34543395-69359AAB-623D-472B-8766-DAB79A57C5ECQ34709971-A0AE62F7-381E-4EC7-A1EA-CF304B1ECFA0Q35061866-F1479CEC-0F0F-4DA4-B82D-4BF1B4D8FA4DQ35167249-D9DB4F78-EF22-4FFB-8047-B9A1B6252BFCQ35843367-66613A57-CFF9-486D-9F1A-70CEB3A23B37Q38489705-9B6E8DAA-372E-44AA-8C79-ACFF16C1E241Q38530086-FA2DA15B-E7C6-466C-94A9-C2EA47892268Q38829509-534FAE2B-7B81-48E2-B165-403AE399334FQ39558302-EAFD7F7E-E6AF-4235-BCEB-4949A732C0E9Q42479062-1B6263AC-9432-495D-8F06-21F72FB0765AQ42646933-9926E58A-70C0-4281-80CE-ECCC89E661DCQ46104666-993FBC3E-0EFA-4F08-A581-3F19AD75D2DCQ53374658-B58B5536-7712-4F0C-B59C-C419D53C670D
P2860
Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activators of PPARs and LXR de ...... ucocorticoids on the epidermis
@en
Activators of PPARs and LXR de ...... cocorticoids on the epidermis.
@nl
type
label
Activators of PPARs and LXR de ...... ucocorticoids on the epidermis
@en
Activators of PPARs and LXR de ...... cocorticoids on the epidermis.
@nl
prefLabel
Activators of PPARs and LXR de ...... ucocorticoids on the epidermis
@en
Activators of PPARs and LXR de ...... cocorticoids on the epidermis.
@nl
P2093
P2860
P1476
Activators of PPARs and LXR de ...... ucocorticoids on the epidermis
@en
P2093
Eung-Ho Choi
Kenneth R Feingold
Mao-Qiang Man
Marianne Demerjian
Peter M Elias
Sandra Chang
P2860
P304
P356
10.1111/J.1600-0625.2009.00841.X
P577
2009-02-19T00:00:00Z